Cargando…

Cost‐effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non‐small cell lung cancer

BACKGROUND: The monoclonal antibody durvalumab, an immune‐checkpoint inhibitor (ICI) antiprogrammed death ligand 1 (PD‐L1), is available for unresectable stage III NSCLC patients as consolidation therapy following induction chemoradiotherapy, with very promising overall survival (OS) and progression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buja, Alessandra, Pasello, Giulia, Schiavon, Marco, De Luca, Giuseppe, Rivera, Michele, Cozzolino, Claudia, De Polo, Anna, Scioni, Manuela, Bortolami, Alberto, Baldo, Vincenzo, Conte, PierFranco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527163/ https://www.ncbi.nlm.nih.gov/pubmed/35971638 http://dx.doi.org/10.1111/1759-7714.14531

Ejemplares similares

Estimated direct costs of non‐small cell lung cancer by stage at diagnosis and disease management phase: A whole‐disease model
por: Buja, Alessandra, et al.
Publicado: (2020)

Novel Nuclear Medicine Imaging Applications in Immuno-Oncology
por: Frega, Stefano, et al.
Publicado: (2020)

Health and healthcare variables associated with Italy's excess mortality during the first wave of the COVID-19 pandemic: An ecological study
por: Buja, Alessandra, et al.
Publicado: (2022)

Demographic and socio-economic factors, and healthcare resource indicators associated with the rapid spread of COVID-19 in Northern Italy: An ecological study
por: Buja, Alessandra, et al.
Publicado: (2020)

Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment
por: Bonanno, Laura, et al.
Publicado: (2016)

Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment
por: Frega, Stefano, et al.
Publicado: (2020)

Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature
por: Polo, Valentina, et al.
Publicado: (2015)

LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer
por: Bonanno, Laura, et al.
Publicado: (2019)

Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization
por: Polo, Valentina, et al.
Publicado: (2016)

SOGS-RA gambling scores and substance use in adolescents
por: Buja, Alessandra, et al.
Publicado: (2017)

Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report
por: Ferro, Alessandra, et al.
Publicado: (2021)

Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome
por: Pavan, Alberto, et al.
Publicado: (2022)

Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
por: Bonanno, Laura, et al.
Publicado: (2022)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations
por: Frega, Stefano, et al.
Publicado: (2017)

Is adherence to the Mediterranean diet associated with good sleep duration in primary-school children?
por: Buja, Alessandra, et al.
Publicado: (2022)

MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data
por: Pasello, Giulia, et al.
Publicado: (2015)

Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience
por: Baldo, Vincenzo, et al.
Publicado: (2016)

Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer
por: Boscolo, Alice, et al.
Publicado: (2020)

Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab
por: Pasello, Giulia, et al.
Publicado: (2022)

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
por: Urso, Loredana, et al.
Publicado: (2017)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
por: Kinehara, Yuhei, et al.
Publicado: (2023)

Pathways connecting socioeconomic variables, substance abuse and gambling behaviour: a cross-sectional study on a sample of Italian high-school students
por: Buja, Alessandra, et al.
Publicado: (2019)

Vascular Involvement in Thymic Epithelial Tumors: Surgical and Oncological Outcomes
por: Comacchio, Giovanni M., et al.
Publicado: (2021)

Breast Cancer Primary Prevention and Diet: An Umbrella Review
por: Buja, Alessandra, et al.
Publicado: (2020)

Use of Information and Communication Technology Strategies to Increase Vaccination Coverage in Older Adults: A Systematic Review
por: Buja, Alessandra, et al.
Publicado: (2023)

Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World
por: Pasello, Giulia, et al.
Publicado: (2022)

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
por: Shaverdian, Narek, et al.
Publicado: (2021)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma
por: Chouieri, Toni
Publicado: (2023)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020)

Durvalumab-induced Severe Gastritis
por: Otohara, Masaya, et al.
Publicado: (2021)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology
por: Candini, Olivia, et al.
Publicado: (2019)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
por: Canova, S., et al.
Publicado: (2022)

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer
por: Zulato, Elisabetta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4s14v0p5k5e22qpl6icc7u7fp0